Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
CADTH
Record ID 32014000805
English
Authors' recommendations:
Based on CDR calculations using a confidential price of $vvvvvv per milligram, the daily cost of the maximum dose of Genotropin ($vvvvvv; 0.16 mg/kg to 0.24 mg/kg per week) is less than that of Humatrope ($77; 0.18 mg/kg to 0.30 mg/kg per week), Nutropin ($64; up to 0.3 mg/kg per week), Saizen ($59; 0.20 mg/kg to 0.27 mg/kg per week), and Omnitrope ($42; 0.18 mg/kg to 0.25 mg/kg per week).
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0333_GenotropinGHD-P_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cost-Benefit Analysis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.